PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL)
An abstract of a study by Arribas et al on PQR309, idelalisib, duvelisib and ibrutinib that lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) is presented. Gene expression profiling was obtained with the lllumina-HumanHT-12 Expression-BeadCh...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2016-12, Vol.69, p.S39-S39 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S39 |
|---|---|
| container_issue | |
| container_start_page | S39 |
| container_title | European journal of cancer (1990) |
| container_volume | 69 |
| creator | Arribas, A Rinaldi, A Spriano, F Tarantelli, C Gaudio, E Bernasconi, E Hillmann, P Kwee, I Stathis, A Fabbro, D Stüssi, G Zucca, E Rossi, D Cmiljanovic, V Bertoni, F |
| description | An abstract of a study by Arribas et al on PQR309, idelalisib, duvelisib and ibrutinib that lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) is presented. Gene expression profiling was obtained with the lllumina-HumanHT-12 Expression-BeadChips and analyzed with limma t-test. A GSEA was performed using the limma-derived gene expression profiling signatures obtained for each drug. The study demonstrated the targeted fundamental pathways of all models sustaining lymphoma cell proliferation and survival. Their early effects on the lymphoma cell transcriptome were very similar, but with varied degree of changes among drugs, possibly reflecting their main targets. |
| doi_str_mv | 10.1016/S0959-8049(16)32697-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2037438684</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0959804916326971</els_id><sourcerecordid>2037438684</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1294-3d76aa5f358003a1d44abee271aeda04236d0d0c88863d8c99f0b79518bcf3af3</originalsourceid><addsrcrecordid>eNo9kduOEzEMhiMEEmXhEZAicdNKO-BM5pDcIG0LuyBV4nwdeRJPN7vpTElmKvomPC7TFvXKtvz7s-yfsdcC3goQ1bsfoEudKSj0XFQLmVe6zsQTNhOq1hmoMn_KZhfJc_YipQcAqFUBM_b367fvEvQ1944CBp98c83duKdTyrFz3DdxHHw3VYHQ8aHnyW99wMg31BGnP7tIKfm-4_Yeuw0l7juOdvB7HMjxZWYpBB78I_H5zXK14M637ZiIT4gNXfqH7e6-3yKff1gvV-vFS_asxZDo1f94xX7dfvy5-pStv9x9Xt2sMytyXWTS1RVi2cpSAUgUriiwIcprgeQQilxWDhxYpVQlnbJat9DUuhSqsa3EVl6xN2fuLva_R0qDeejH2E0rTQ6yLqSqVDGpyrPKxj6lSK3ZRb_FeDACzNEEczLBHD9spupkghHT3PvzHE0n7D1FY8P0SovhkQ6ULquESbmBM-TIENWJIOQ_fJGObw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2037438684</pqid></control><display><type>article</type><title>PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL)</title><source>Access via ScienceDirect (Elsevier)</source><creator>Arribas, A ; Rinaldi, A ; Spriano, F ; Tarantelli, C ; Gaudio, E ; Bernasconi, E ; Hillmann, P ; Kwee, I ; Stathis, A ; Fabbro, D ; Stüssi, G ; Zucca, E ; Rossi, D ; Cmiljanovic, V ; Bertoni, F</creator><creatorcontrib>Arribas, A ; Rinaldi, A ; Spriano, F ; Tarantelli, C ; Gaudio, E ; Bernasconi, E ; Hillmann, P ; Kwee, I ; Stathis, A ; Fabbro, D ; Stüssi, G ; Zucca, E ; Rossi, D ; Cmiljanovic, V ; Bertoni, F</creatorcontrib><description>An abstract of a study by Arribas et al on PQR309, idelalisib, duvelisib and ibrutinib that lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) is presented. Gene expression profiling was obtained with the lllumina-HumanHT-12 Expression-BeadChips and analyzed with limma t-test. A GSEA was performed using the limma-derived gene expression profiling signatures obtained for each drug. The study demonstrated the targeted fundamental pathways of all models sustaining lymphoma cell proliferation and survival. Their early effects on the lymphoma cell transcriptome were very similar, but with varied degree of changes among drugs, possibly reflecting their main targets.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/S0959-8049(16)32697-1</identifier><language>eng</language><publisher>Oxford: Elsevier Science Ltd</publisher><subject>B-cell lymphoma ; Cancer therapies ; Cell culture ; Cell growth ; Cell proliferation ; Cell survival ; Gene expression ; Hematology, Oncology and Palliative Medicine ; Inhibitor drugs ; Lymphocytes B ; Lymphoma</subject><ispartof>European journal of cancer (1990), 2016-12, Vol.69, p.S39-S39</ispartof><rights>Elsevier Ltd</rights><rights>Copyright Elsevier Science Ltd. Dec 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,782,786,27933,27934</link.rule.ids></links><search><creatorcontrib>Arribas, A</creatorcontrib><creatorcontrib>Rinaldi, A</creatorcontrib><creatorcontrib>Spriano, F</creatorcontrib><creatorcontrib>Tarantelli, C</creatorcontrib><creatorcontrib>Gaudio, E</creatorcontrib><creatorcontrib>Bernasconi, E</creatorcontrib><creatorcontrib>Hillmann, P</creatorcontrib><creatorcontrib>Kwee, I</creatorcontrib><creatorcontrib>Stathis, A</creatorcontrib><creatorcontrib>Fabbro, D</creatorcontrib><creatorcontrib>Stüssi, G</creatorcontrib><creatorcontrib>Zucca, E</creatorcontrib><creatorcontrib>Rossi, D</creatorcontrib><creatorcontrib>Cmiljanovic, V</creatorcontrib><creatorcontrib>Bertoni, F</creatorcontrib><title>PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL)</title><title>European journal of cancer (1990)</title><description>An abstract of a study by Arribas et al on PQR309, idelalisib, duvelisib and ibrutinib that lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) is presented. Gene expression profiling was obtained with the lllumina-HumanHT-12 Expression-BeadChips and analyzed with limma t-test. A GSEA was performed using the limma-derived gene expression profiling signatures obtained for each drug. The study demonstrated the targeted fundamental pathways of all models sustaining lymphoma cell proliferation and survival. Their early effects on the lymphoma cell transcriptome were very similar, but with varied degree of changes among drugs, possibly reflecting their main targets.</description><subject>B-cell lymphoma</subject><subject>Cancer therapies</subject><subject>Cell culture</subject><subject>Cell growth</subject><subject>Cell proliferation</subject><subject>Cell survival</subject><subject>Gene expression</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Inhibitor drugs</subject><subject>Lymphocytes B</subject><subject>Lymphoma</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo9kduOEzEMhiMEEmXhEZAicdNKO-BM5pDcIG0LuyBV4nwdeRJPN7vpTElmKvomPC7TFvXKtvz7s-yfsdcC3goQ1bsfoEudKSj0XFQLmVe6zsQTNhOq1hmoMn_KZhfJc_YipQcAqFUBM_b367fvEvQ1944CBp98c83duKdTyrFz3DdxHHw3VYHQ8aHnyW99wMg31BGnP7tIKfm-4_Yeuw0l7juOdvB7HMjxZWYpBB78I_H5zXK14M637ZiIT4gNXfqH7e6-3yKff1gvV-vFS_asxZDo1f94xX7dfvy5-pStv9x9Xt2sMytyXWTS1RVi2cpSAUgUriiwIcprgeQQilxWDhxYpVQlnbJat9DUuhSqsa3EVl6xN2fuLva_R0qDeejH2E0rTQ6yLqSqVDGpyrPKxj6lSK3ZRb_FeDACzNEEczLBHD9spupkghHT3PvzHE0n7D1FY8P0SovhkQ6ULquESbmBM-TIENWJIOQ_fJGObw</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Arribas, A</creator><creator>Rinaldi, A</creator><creator>Spriano, F</creator><creator>Tarantelli, C</creator><creator>Gaudio, E</creator><creator>Bernasconi, E</creator><creator>Hillmann, P</creator><creator>Kwee, I</creator><creator>Stathis, A</creator><creator>Fabbro, D</creator><creator>Stüssi, G</creator><creator>Zucca, E</creator><creator>Rossi, D</creator><creator>Cmiljanovic, V</creator><creator>Bertoni, F</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20161201</creationdate><title>PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL)</title><author>Arribas, A ; Rinaldi, A ; Spriano, F ; Tarantelli, C ; Gaudio, E ; Bernasconi, E ; Hillmann, P ; Kwee, I ; Stathis, A ; Fabbro, D ; Stüssi, G ; Zucca, E ; Rossi, D ; Cmiljanovic, V ; Bertoni, F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1294-3d76aa5f358003a1d44abee271aeda04236d0d0c88863d8c99f0b79518bcf3af3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>B-cell lymphoma</topic><topic>Cancer therapies</topic><topic>Cell culture</topic><topic>Cell growth</topic><topic>Cell proliferation</topic><topic>Cell survival</topic><topic>Gene expression</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Inhibitor drugs</topic><topic>Lymphocytes B</topic><topic>Lymphoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Arribas, A</creatorcontrib><creatorcontrib>Rinaldi, A</creatorcontrib><creatorcontrib>Spriano, F</creatorcontrib><creatorcontrib>Tarantelli, C</creatorcontrib><creatorcontrib>Gaudio, E</creatorcontrib><creatorcontrib>Bernasconi, E</creatorcontrib><creatorcontrib>Hillmann, P</creatorcontrib><creatorcontrib>Kwee, I</creatorcontrib><creatorcontrib>Stathis, A</creatorcontrib><creatorcontrib>Fabbro, D</creatorcontrib><creatorcontrib>Stüssi, G</creatorcontrib><creatorcontrib>Zucca, E</creatorcontrib><creatorcontrib>Rossi, D</creatorcontrib><creatorcontrib>Cmiljanovic, V</creatorcontrib><creatorcontrib>Bertoni, F</creatorcontrib><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Arribas, A</au><au>Rinaldi, A</au><au>Spriano, F</au><au>Tarantelli, C</au><au>Gaudio, E</au><au>Bernasconi, E</au><au>Hillmann, P</au><au>Kwee, I</au><au>Stathis, A</au><au>Fabbro, D</au><au>Stüssi, G</au><au>Zucca, E</au><au>Rossi, D</au><au>Cmiljanovic, V</au><au>Bertoni, F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL)</atitle><jtitle>European journal of cancer (1990)</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>69</volume><spage>S39</spage><epage>S39</epage><pages>S39-S39</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>An abstract of a study by Arribas et al on PQR309, idelalisib, duvelisib and ibrutinib that lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) is presented. Gene expression profiling was obtained with the lllumina-HumanHT-12 Expression-BeadChips and analyzed with limma t-test. A GSEA was performed using the limma-derived gene expression profiling signatures obtained for each drug. The study demonstrated the targeted fundamental pathways of all models sustaining lymphoma cell proliferation and survival. Their early effects on the lymphoma cell transcriptome were very similar, but with varied degree of changes among drugs, possibly reflecting their main targets.</abstract><cop>Oxford</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/S0959-8049(16)32697-1</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2016-12, Vol.69, p.S39-S39 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_journals_2037438684 |
| source | Access via ScienceDirect (Elsevier) |
| subjects | B-cell lymphoma Cancer therapies Cell culture Cell growth Cell proliferation Cell survival Gene expression Hematology, Oncology and Palliative Medicine Inhibitor drugs Lymphocytes B Lymphoma |
| title | PQR309, idelalisib, duvelisib and ibrutinib lead to similar gene expression changes in activated B-cell like (ABC) diffuse large B-cell lymphoma (DLBCL) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T22%3A03%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PQR309,%20idelalisib,%20duvelisib%20and%20ibrutinib%20lead%20to%20similar%20gene%20expression%20changes%20in%20activated%20B-cell%20like%20(ABC)%20diffuse%20large%20B-cell%20lymphoma%20(DLBCL)&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Arribas,%20A&rft.date=2016-12-01&rft.volume=69&rft.spage=S39&rft.epage=S39&rft.pages=S39-S39&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/S0959-8049(16)32697-1&rft_dat=%3Cproquest_cross%3E2037438684%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2037438684&rft_id=info:pmid/&rft_els_id=1_s2_0_S0959804916326971&rfr_iscdi=true |